UK unable to throw money at the situation
Fund will invest in a range of 35-40 companies
New drug launches need private finance
Most Q1 IPOs since 2007
The accelerated approval of the first new Alzheimer's treatment in almost two decades looks set to drive a new wave of biotech innovation and investment.
Covering two key megatrends
How data will prove key in sector's success
Managed by Mike Clulow and US growth equity team
Disgraced manager bullish on healthcare prospects